Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.39 |
| ▸ | CTSS | P25774 | 2/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1709086 | 0.88 | CTSK (0.38) | CTSKCTSSGABRB1GABRB2AAK1 | |
| SCHEMBL16254012 | 0.88 | CTSK (0.38) | CTSKCTSSGABRB1GABRB2AAK1 | |
| SCHEMBL17302048 | 0.76 | S1PR3 (0.43) | CTSKCTSSGABRB1GABRB2RAB9A | |
| SCHEMBL1709045 | 0.76 | TRPA1 (0.41) | CTSKCTSSAAK1MAPTS1PR3 | |
| SCHEMBL1708913 | 0.76 | TRPA1 (0.41) | CTSKCTSSAAK1MAPTS1PR3 | |
| SCHEMBL1699000 | 0.76 | TRPA1 (0.41) | CTSKCTSSAAK1MAPTS1PR3 | |
| SCHEMBL17302049 | 0.76 | AAK1 (0.41) | CTSKCTSSAAK1MEN1RAB9A | |
| SCHEMBL17301886 | 0.76 | AAK1 (0.41) | CTSKCTSSAAK1MEN1RAB9A | |
| SCHEMBL17302203 | 0.76 | AAK1 (0.41) | CTSKCTSSAAK1MEN1RAB9A | |
| SCHEMBL16239369 | 0.76 | ALDH1A1 (0.41) | MEN1KMT2AMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889863-B2 | Stereoselective methods, catalysts and intermediates for the synthesis of (−)-Nutlin-3 and related compounds | VANDERBILT UNIVERSITY (US) | 2014-11-18 | — | — | US | disclosed |
| US-20120088915-A1 | STEREOSELECTIVE METHODS, CATALYSTS AND INTERMEDIATES FOR THE SYNTHESIS OF (-)-NUTLIN-3 AND RELATED COMPOUNDS | VANDERBILT UNIVERSITY | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088915-A1 | STEREOSELECTIVE METHODS, CATALYSTS AND INTERMEDIATES FOR THE SYNTHESIS OF (-)-NUTLIN-3 AND RELATED COMPOUNDS | NUTF2, MDM2, CIAPIN1 | CTSK 2403/4885CTSS 1005/4885GABRB1 4129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.